Sec Form 4 Filing - BRADSHER NEAL C @ QUESTCOR PHARMACEUTICALS INC - 2013-11-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BRADSHER NEAL C 2. Issuer Name and Ticker or Trading Symbol QUESTCOR PHARMACEUTICALS INC [ QCOR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O BROADWOOD CAPITAL INC., 724 FIFTH AVENUE, 9TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 11/14/2013 (Street) NEW YORK, NY10019 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 11/14/2013 M 15,000 A $ 0.9 19,183 ( 5 ) D ( 3 ) Common Stock 11/14/2013 M 25,000 A $ 0.83 44,183 D ( 3 ) Common Stock 11/14/2013 S 15,000 D $ 62.3111 ( 1 ) 29,183 D ( 3 ) Common Stock 11/14/2013 S 25,000 D $ 62.4628 ( 2 ) 4,183 D ( 3 ) Common Stock 2,796,660 I Footnote ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares OPTION TO PURCHASE COMMON SHARES $ 0.9 11/14/2013 M 15,000 ( 6 ) 03/25/2014 COMMON SHARES 15,000 ( 7 ) 0 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 0.83 11/14/2013 M 25,000 ( 6 ) 03/09/2014 COMMON SHARES 25,000 ( 7 ) 0 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 34.86 ( 8 ) 05/24/2023 COMMON SHARES 9,203 9,203 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 40.37 ( 6 ) 05/09/2022 COMMON SHARES 15,214 15,214 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 14.73 ( 6 ) 12/31/2020 COMMON SHARES 17,500 17,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 14.73 ( 9 ) 12/31/2020 COMMON SHARES 15,000 15,000 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 4.75 ( 6 ) 12/31/2019 COMMON SHARES 17,500 17,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 4.75 ( 9 ) 12/31/2019 COMMON SHARES 15,000 15,000 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 9.31 ( 6 ) 12/31/2018 COMMON SHARES 32,500 32,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 5.77 ( 6 ) 12/31/2017 COMMON SHARES 32,500 32,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 1.47 ( 6 ) 12/31/2016 COMMON SHARES 32,500 32,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 1.04 ( 6 ) 12/31/2015 COMMON SHARES 32,500 32,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 0.53 ( 6 ) 12/31/2014 COMMON SHARES 32,500 32,500 D ( 3 ) OPTION TO PURCHASE COMMON SHARES $ 0.84 ( 6 ) 05/16/2014 COMMON SHARES 7,500 7,500 D ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BRADSHER NEAL C C/O BROADWOOD CAPITAL INC. 724 FIFTH AVENUE, 9TH FLOOR NEW YORK, NY10019 X Signatures /s/ Neal C. Bradsher 11/15/2013 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This constitutes the weighted average sale price. The prices range from $62.31 to $62.39. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. ( 2 )This constitutes the weighted average sale price. The prices range from $62.46 to $62.54. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. ( 3 )These securities are owned by Neal C. Bradsher, who is the Reporting Person. ( 4 )The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. ( 5 )Includes a restricted stock award of 4,183 shares granted to Neal C. Bradsher on May 24, 2013 under the Questcor Pharmaceuticals, Inc. (the "Company") 2006 Equity Incentive Award Plan, and that were inadvertently omitted from Form 4 filings made by Broadwood Partners, L.P. on June 17th, 2013 and November 13th, 2013. The shares will vest in full upon the earlier to occur of (i) May 24th, 2014 or (ii) the Company's 2014 Annual Shareholders' Meeting. ( 6 )These options are currently exercisable. ( 7 )Options granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan. ( 8 )These options vest in equal monthly installments over one year from the time of the grant. ( 9 )These options vest monthly over 48 months from the time of the grant.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.